Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Ford Investor Services, Inc.
$12.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Verastem Inc Announces President Change-Form 8-K


Tuesday, 22 Jan 2013 02:58pm EST 

Verastem Inc reported in its Form 8-K that on January 18, 2013, Verastem, Inc. (Company) appointed Robert Forrester as President of the Company. Mr. Forrester will continue to serve as Chief Operating Officer of the Company. Christoph Westphal, M.D., Ph.D. previously served as President and will remain Chief Executive Officer (CEO) of the Company. 

Latest Key Developments in Pharmaceuticals

Company Quote

8.64
0.16 +1.89%
11 Jul 2014